GRI
GRI Bio, Inc.
$2.24
-0.22%
2026-05-08
About GRI Bio, Inc.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Key Fundamentals
Forward P/E
-0.28
EPS (TTM)
$-121.80
ROE
-238.2%
Profit Margin
0.0%
Debt/Equity
1.18
Price/Book
0.19
Beta
-0.77
Market Cap
$3.3M
Avg Volume (10D)
41K
Recent Breakout Signals
No recent breakout signals detected for GRI.
Recent Price Range (60 Days)
60D High
$2.97
60D Low
$2.10
Avg Volume
86K
Latest Close
$2.24
Get breakout alerts for GRI
Sign up for Breakout Scanner to receive daily notifications when GRI triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
GRI Bio, Inc. (GRI) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors GRI daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. GRI operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.